Fennec Pharmaceuticals Inc. FENC
Institutional shares held
14.4 Million
53.2K
calls
83.9K
puts
Total value of holdings
$97.9M
$360K
calls
$568K
puts
Market Cap
$177M
26,067,300
Shares Out.
Institutional ownership
55.38%
# of Institutions
69
We take great care to ensure that the data presented and summarized in this overview for FENNEC PHARMACEUTICALS INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding FENC
View all-
Southpoint Capital Advisors LP New York, NY4.08MShares$27.6 Million1.02% of portfolio
-
Sonic Gp LLC Honolulu, HI2.41MShares$16.3 Million35.34% of portfolio
-
Dg Capital Management, LLC New York, NY1.51MShares$10.2 Million10.39% of portfolio
-
Solas Capital Management, LLC Darien, CT1.11MShares$7.53 Million8.43% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.01MShares$6.87 Million0.0% of portfolio
-
Black Rock Inc. New York, NY927KShares$6.29 Million0.0% of portfolio
-
Aigh Capital Management LLC Baltimore, MD570KShares$3.87 Million2.56% of portfolio
-
Harbert Fund Advisors, Inc. Birmingham, AL467KShares$3.17 Million3.57% of portfolio
-
State Street Corp Boston, MA304KShares$2.06 Million0.0% of portfolio
-
Gendell Jeffrey L Greenwich, CT302KShares$2.05 Million0.13% of portfolio
Latest Institutional Activity in FENC
Top Purchases
Top Sells
About FENC
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
Insider Transactions at FENC
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 01
2024
|
Rosty Raykov CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
2,431
-1.28%
|
$21,879
$9.11 P/Share
|
|
Apr 30
2024
|
Robert Andrade CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
1,042
+0.98%
|
-
|
|
Apr 30
2024
|
Rosty Raykov CHIEF EXECUTIVE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
2,431
+1.26%
|
-
|
|
Apr 22
2024
|
Adrian Haigh CHIEF OPERATING OFFICER |
SELL
Open market or private sale
|
Direct |
22,223
-100.0%
|
$200,007
$9.32 P/Share
|
|
Apr 22
2024
|
Adrian Haigh CHIEF OPERATING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
22,223
+50.0%
|
$44,446
$2.31 P/Share
|
|
Apr 19
2024
|
Adrian Haigh CHIEF OPERATING OFFICER |
SELL
Open market or private sale
|
Direct |
22,222
-100.0%
|
$199,998
$9.34 P/Share
|
|
Apr 19
2024
|
Adrian Haigh CHIEF OPERATING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
22,222
+50.0%
|
$44,444
$2.31 P/Share
|
|
Apr 18
2024
|
Adrian Haigh CHIEF OPERATING OFFICER |
SELL
Open market or private sale
|
Direct |
22,222
-100.0%
|
$199,998
$9.62 P/Share
|
|
Apr 18
2024
|
Adrian Haigh CHIEF OPERATING OFFICER |
BUY
Open market or private sale
|
Direct |
22,222
+33.33%
|
$44,444
$2.31 P/Share
|
|
Apr 17
2024
|
Adrian Haigh CHIEF OPERATING OFFICER |
SELL
Open market or private sale
|
Direct |
22,222
-50.0%
|
$199,998
$9.91 P/Share
|
|
Apr 17
2024
|
Adrian Haigh CHIEF OPERATING OFFICER |
BUY
Open market or private sale
|
Direct |
22,222
+50.0%
|
$44,444
$2.31 P/Share
|
|
Apr 16
2024
|
Adrian Haigh CHIEF OPERATING OFFICER |
SELL
Open market or private sale
|
Direct |
22,222
-100.0%
|
$222,220
$10.28 P/Share
|
|
Apr 16
2024
|
Adrian Haigh CHIEF OPERATING OFFICER |
BUY
Open market or private sale
|
Direct |
22,222
+33.33%
|
$44,444
$2.31 P/Share
|
|
Apr 15
2024
|
Adrian Haigh CHIEF OPERATING OFFICER |
SELL
Open market or private sale
|
Direct |
22,222
-50.0%
|
$222,220
$10.3 P/Share
|
|
Apr 15
2024
|
Adrian Haigh CHIEF OPERATING OFFICER |
BUY
Open market or private sale
|
Direct |
22,222
+50.0%
|
$44,444
$2.31 P/Share
|
|
Apr 15
2024
|
Chris A Rallis |
BUY
Exercise of conversion of derivative security
|
Direct |
1,389
+2.94%
|
$13,890
$10.45 P/Share
|
|
Apr 15
2024
|
Chris A Rallis |
SELL
Open market or private sale
|
Direct |
800
-1.77%
|
$8,000
$10.45 P/Share
|
|
Apr 05
2024
|
Rosty Raykov CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
44,300
-19.11%
|
$443,000
$10.75 P/Share
|
|
Apr 04
2024
|
Rosty Raykov CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
44,283
-8.32%
|
$442,830
$10.89 P/Share
|
|
Apr 03
2024
|
Rosty Raykov CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
40,584
-6.61%
|
$405,840
$10.78 P/Share
|
Last 12 Months Summary
Buy / Acquisition
531K
Shares
From
10
Insiders
| Exercise of conversion of derivative security | 397K shares |
|---|---|
| Grant, award, or other acquisition | 3.47K shares |
| Open market or private purchase | 41.7K shares |
| Open market or private sale | 88.9K shares |
Sell / Disposition
391K
Shares
From
4
Insiders
| Open market or private sale | 391K shares |
|---|